



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-164/S-083

Sanofi-Aventis Inc.
Attention: Jim Wang, Ph.D.
Regulatory Development Project Leader
9 Great Valley Parkway,
Malvern, PA 19355

Dear Dr. Wang:

Please refer to your supplemental new drug application dated January 29, 2009, received January 29, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lovenox[®] (enoxaparin sodium).

We acknowledge receipt of your submission dated July 15, and 22, 2009.

Your submission of January 29, 2009, constituted a complete response to our August 20, 2008, action letter.

This supplemental new drug application provides for revisions to several aspects of the package insert to improve readability and consistency with the content and format specified by 21 CFR 201.56 and associated guidance documents (available at <http://www.fda.gov/cder/regulatory/physLabel/default.htm>) in order to furnish adequate information for the safe and effective use of the drug.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert submitted July 22, 2009).

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the submitted labeling (package insert submitted July 22, 2009). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, **“SPL for approved sNDA 20-164/S-083.”**

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to Division of Medical Imaging and Hematology Products and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have questions, contact Marcus Cato, Regulatory Project Manager, at (301) 796-3903.

Sincerely,

{See appended electronic signature page}

Rafel Dwaine Rieves, MD
Director
Division of Medical Imaging and Hematology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

Enclosure: Package Insert

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Rafel Rieves

7/23/2009 08:14:04 AM